Abstract:        Obesity, a growing global issue, has been closely associated with an increased risk of various cancers, especially breast cancer. El ...

Explore how cutting-edge agents like alpelisib, capivasertib, MEK and ERK inhibitors, and JAK inhibitors are reshaping the ...

Combining two FDA-approved cancer drugs trametinib and rapamycin increases the lifespan of mice by an amazing 30%, according ...

NEW YORK, NY, USA I May 30, 2025 I Pfizer Inc. (NYSE: PFE) today announced statistically significant and clinically meaningful survival results from the Phase ...

Pfizer Inc. (NYSE: PFE) today announced statistically significant and clinically meaningful survival results from the Phase 3 ...

Researchers at the Max Planck Institute for Biology of Aging have discovered that the combination of the two cancer drugs, ...

Creative Biolabs recently updated its antibody chip platform, expanding product arrays for phosphorylation signaling and ...

Exploration of extending ketamine’s antidepressant effects by enhancing intracellular signaling pathways in major depressive ...

Roughly 10 percent of the U.S. population is afflicted with major depressive disorder at any given time, and up to 20 percent will exhibit MDD symptoms over their lifetimes.

Targeting ERK signaling through DUSP6 inhibition extended the antidepressant effects of a single ketamine dose in mice. Findings indicate that transiently increasing ERK activity may sustain ...